Cargando…
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
OBJECTIVE: To synthesize current evidence of the impact of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on hypoglycemia, treatment discontinuation and glycemic level in patients with type 2 diabetes. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Literature search (Medli...
Autores principales: | Li, Zhixia, Zhang, Yuan, Quan, Xiaochi, Yang, Zhirong, Zeng, Xiantao, Ji, Linong, Sun, Feng, Zhan, Siyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861281/ https://www.ncbi.nlm.nih.gov/pubmed/27158818 http://dx.doi.org/10.1371/journal.pone.0154206 |
Ejemplares similares
-
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Sun, Feng, et al.
Publicado: (2015) -
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018) -
Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
por: Cai, Xiaoling, et al.
Publicado: (2021) -
Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis
por: Liu, Yufang, et al.
Publicado: (2019) -
Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)